Last reviewed · How we verify
Preventive administration of Rapaflo
Rapaflo (silodosin) is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow.
Rapaflo (silodosin) is an alpha-1A adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow. Used for Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms — preventive/early intervention.
At a glance
| Generic name | Preventive administration of Rapaflo |
|---|---|
| Also known as | Rapaflo, Silodosin |
| Sponsor | Sir Mortimer B. Davis - Jewish General Hospital |
| Drug class | Alpha-1A adrenergic receptor antagonist |
| Target | Alpha-1A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Urology |
| Phase | Phase 3 |
Mechanism of action
Silodosin selectively blocks alpha-1A adrenergic receptors located in the prostate and bladder outlet, reducing smooth muscle tone and urinary obstruction. This mechanism alleviates lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). The preventive administration approach in this trial likely aims to evaluate whether early treatment can delay symptom progression or disease advancement.
Approved indications
- Benign prostatic hyperplasia (BPH) with lower urinary tract symptoms — preventive/early intervention
Common side effects
- Retrograde ejaculation
- Dizziness
- Diarrhea
- Orthostatic hypotension
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: